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Transient increases in nucleus accumbens (NAc)
dopamine concentration are observed when animals
are presented with motivationally salient stimuli and
are theorized to energize reward seeking. They arise
from high-frequency firing of dopamine neurons in
the ventral tegmental area (VTA), which also results
in the release of endocannabinoids from dopamine
cell bodies. In this context, endocannabinoids are
thought to regulate reward seeking by modulating
dopamine signaling, although a direct link has never
been demonstrated. To test this, we pharmacologi-
cally manipulated endocannabinoid neurotransmis-
sion in the VTA while measuring transient changes
in dopamine concentration in the NAc during reward
seeking. Disrupting endocannabinoid signaling dra-
matically reduced, whereas augmenting levels of
the endocannabinoid 2-arachidonoylglycerol (2AG)
increased, cue-evoked dopamine concentrations
and reward seeking. These data suggest that 2AG
in the VTA regulates reward seeking by sculpting
ethologically relevant patterns of dopamine release
during reward-directed behavior.
INTRODUCTION
The neural mechanisms responsible for the pursuit of rewards in
the environment are essential for the survival of the organism
(Nesse and Berridge, 1997; Schultz et al., 1997). Environmental
stimuli that predict the availability of reward develop incentive-
motivational properties that energize the seeking of future
rewards (Bindra, 1968). The NAc is a neural substrate that is crit-
ically involved in integrating interoceptive and environmental360 Neuron 73, 360–373, January 26, 2012 ª2012 Elsevier Inc.information with emotional information to initiate reward seeking
(Kelley, 1999; Mogenson et al., 1980). When reward seeking is
maintained in a controlled experimental setting in which environ-
mental stimuli predict reward availability, transient dopamine
surges in the NAc begin to occur in response to the predictive
stimuli (i.e., conditioned cues) following the attribution of incen-
tive salience (Berridge and Robinson, 1998; Flagel et al., 2011).
These transient increases in dopamine have been detected in
the NAc when animals are presented with cues predicting
various rewards—including drugs of abuse (Phillips et al.,
2003), food (Roitman et al., 2004), and brain stimulation reward
(Cheer et al., 2007a)—and are required to promote reward-
directed behavior (Nicola, 2010).
The brain endocannabinoid system, formed by metabotropic
cannabinoid receptors (CB1 and CB2) and their endogenous
ligands (e.g., anandamide and 2AG), is important for the
regulation of dopamine signaling during reinforcement process-
ing (Lupica and Riegel, 2005; Solinas et al., 2008). When
dopamine neurons in the VTA exhibit brief high-frequency
firing episodes they release endocannabinoids that act as retro-
grade messengers by binding to pre-synaptic CB1 receptors,
thereby indirectly modulating the excitability of dopamine
neurons by reducing presynaptic neurotransmitter release (Me-
lis et al., 2004). Rather than being released through a vesicular
mechanism, endocannabinoids are distinct from other neuro-
transmitters in that they are formed and released ‘‘on demand’’
during specific neural events (Freund et al., 2003). It is likely,
therefore, that endocannabinoids regulate dopamine signaling
during reward seeking exclusively in situations in which dopa-
mine neurons fire at high frequencies—like when animals are
presented with environmental cues predicting reward (Schultz
et al., 1997).
To investigate whether endocannabinoids modulate the
neural mechanisms of reward seeking, we measured changes
in the concentration of cue-evoked dopamine transients in the
NAc shell while pharmacologically altering endocannabinoid
signaling during operant behavior. A pharmacological approach
AC D
B Figure 1. Reward Seeking and Cue-Evoked Dopa-
mine Release Events Are Strengthened across
Trials
(A) Pavlovian associations sculpt patterns of transient
dopamine release in response to a predictive cue during
reward seeking. A representative surface-plot shows
changes in dopamine concentration (z axis) occurring
across trials (y axis) while responding is maintained by
brain stimulation reward in an ICSS task. Cue presenta-
tion, which is indicated by the gray rectangle, occurred for
1 s prior to lever extension.
(B) Representative traces show the mean cue-evoked
dopamine concentration increasing across trials. Each
dopamine concentration trace represents the mean of 30
consecutive trials.
(C and D) The conditioned cue begins to strengthen
reward seeking as the concentration of cue-evoked
dopamine increases across trials. Linear regression anal-
yses show increases inmean dopamine concentration and
decreases in response latency across binned responses.
Dashed lines represent the 95% confidence region.
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CB1 receptors using rimonabant (a CB1 receptor antagonist)
reduced drug-induced transient dopamine release into the NAc
(Cheer et al., 2007b). Operant behavior was maintained by either
brain stimulation reward or food reinforcement while an environ-
mental cue signaled the availability of reward. We found that
disrupting endocannabinoid signaling uniformly decreased the
concentration of cue-evoked dopamine transients and reward
seeking. These findings prompted us to investigate whether
increasing endocannabinoid levels would facilitate reward
seeking, and if so, which endocannabinoid is responsible. Using
recently developed pharmacological tools designed to manipu-
late specific components of the endocannabinoid system, we
found that augmenting 2AG, but not anandamide, levels by
disrupting metabolic enzyme activity increased dopamine
signaling during reward seeking—suggesting that 2AG sculpts
ethologically relevant patterns of dopamine release during
reward-directed behavior.
RESULTS
Transient Dopamine Concentrations Time Locked
to Cue Presentation Develop across Trials
Dopamine was measured in the NAc shell using fast-scan cyclic
voltammetry (FSCV) while responding was maintained in a previ-
ously described intra-cranial self-stimulation (ICSS) task (Cheer
et al., 2007a). As in our previous report (Cheer et al., 2007a),Neuron 73, 36a compound cue predicted reward availability.
This occurred across multiple sensory modali-
ties; specifically, a house light turned off, an
ongoing tone ceased, and then 1 s later a white
stimulus light mounted above the lever was pre-
sented simultaneously with lever extension. A
10 s timeout followed each lever response.
Under these conditions, electrically-evoked
dopamine release occurred following a leverresponse and was temporally dissociable from cue-evoked
dopamine release events, allowing for changes in the concentra-
tion of cue-evoked dopamine to be measured across trials. In
agreement with previous studies (Day et al., 2007; Owesson-
White et al., 2008), the concentration of dopamine occurring in
response to the cue during this acquisition session increased
across trials (Figures 1A and 1B). While the concentration of
cue-evoked dopamine rapidly increased (Figure 1C; R2 = 0.85;
n = 5), the latency to respond from lever extension (a metric of
reward seeking) decreased in a linear fashion (Figure 1D;
R2 = 0.80; n = 5; mean values: 7.18, 7.16, 6.91, 6.81 s), demon-
strating that the strengthening of Pavlovian associations
between the cue and unconditioned stimulus is accompanied
by increased and cue-related dopamine signaling (Day et al.,
2007). Importantly, increased recruitment of endocannabinoids
in the VTA should develop in association with an increasing
concentration of cue-evoked dopamine release. As dopamine
neurons fire in high frequency bursts, voltage gated Ca2+ ion
channels open and the resulting Ca2+ influx activates the
enzymes responsible for the synthesis of endocannabinoids
(Wilson and Nicoll, 2002). Thus, endocannabinoid levels should
be highest in the VTA after periods of phasic dopamine neural
activity. If endocannabinoids are indeed involved in modulating
dopamine signaling during reward seeking, pharmacological
disruption of endocannabinoids should decrease cue-evoked
dopamine concentrations and cue-motivated responding in
unison.0–373, January 26, 2012 ª2012 Elsevier Inc. 361
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Figure 2. Disrupting Endocannabinoid Signaling Decreases Cue-
Evoked Dopamine Concentrations during Reward Seeking in an
ICSS Task
(A) Response latency (a metric of reward seeking) for brain stimulation reward
maintained in the ICSS task. A high (0.3 mg/kg i.v.; red bar) but not low
(0.125 mg/kg i.v.; orange bar) dose of rimonabant increased the latency to
respond for brain stimulation reward in comparison to vehicle (v, blue bar).
(B) Mean dopamine concentration observed during the first second of cue
presentation under baseline (b), vehicle (v), and drug conditions. Rimonabant
at a high (0.3mg/kg i.v.; red bar) but not low (0.125mg/kg i.v.; orange bar) dose
Neuron
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362 Neuron 73, 360–373, January 26, 2012 ª2012 Elsevier Inc.Disrupting Endocannabinoid Signaling during ICSS
Decreases Cue-Evoked Dopamine Concentrations
and Reward Seeking
To assess the effects of disrupting endocannabinoid signaling on
cue-evoked dopamine concentrations and reward seeking, we
treated rats with the CB1 receptor antagonist rimonabant while
responding was maintained by brain stimulation reward in an
ICSS task. Following the establishment of stable baseline
concentrations of cue-evoked dopamine release, animals were
given access to 30 stimulations for each component of the
session (i.e., baseline, vehicle, and drug treatment). A high
(0.3 mg/kg i.v.; MWU test, U = 3, p < 0.01; n = 15; mean values:
b = 0.91, v = 1.09, rimo = 2.45 s) but not low (0.125 mg/kg i.v.)
rimonabant dose increased the latency to respond for brain
stimulation reward (Figure 2A) in comparison to vehicle treat-
ment. The increase in response latency was accompanied by
a decrease in the concentration of cue-evoked dopamine (Fig-
ure 2B; F(2,44) = 5.40, p < 0.01; 0.3 mg/kg versus vehicle, p =
0.02; also see Figure S1A available online for mean dopamine
concentration traces). Cue-evoked dopamine concentrations
were not affected by the lower rimonabant dose (Figure 2B;
0.125 mg/kg i.v.). Representative color plots and accompanying
dopamine concentration traces (Figure 2C) show rimonabant
(0.3 mg/kg i.v.) decreasing cue-evoked dopamine events during
individual trials, whereas the representative surface plot (Fig-
ure 2D) illustrates the effect of rimonabant (0.3 mg/kg i.v.) on
dopamine concentrations across trials. We further determined
that the decreases in reward seeking and cue-evoked dopamine
concentration could not be explained by a drug-induced effect
on electrically-evoked dopamine release (Figure S1B), consis-
tent with an absence of CB1 receptors on dopamine terminals
(Julian et al., 2003) and could be replicated using the moredecreased the concentration of cue-evoked dopamine in comparison to
vehicle.
(C) Representative color plots (top) and dopamine concentration traces
(bottom) show the effects of rimonabant on cue-evoked dopamine events in
individual trials. Top: Representative color plots topographically depict the
voltammetric data with time on the x axis, applied scan potential (Eapp) on the
y axis and background-subtracted faradaic current shown on the z-axis in
pseudocolor. Dopamine can be identified by an oxidation peak (green)
at +0.6 V and a smaller reduction peak (yellow) at 0.2 V. Bottom: Corre-
sponding traces show the concentration of dopamine (nM) detected at the
time of cue presentation (gray bar) following vehicle (left; blue trace) and
rimonabant (right; red trace) administration.
(D) A representative surface-plot shows changes in dopamine concentration (z
axis) across trials (y axis) during baseline (black line), vehicle (blue line), and
rimonabant (red line) conditions. Data are centered around lever presentation
on the x axis.
(E) Disrupting endocannabinoid signaling within the VTA is sufficient to
decrease reward seeking. Intrategmental rimonabant (200 ng i.c.; red bar)
significantly increased response latency in comparison to vehicle (v, blue bar).
(F) Mean dopamine concentrations observed during first second of cue-
presentation under baseline (b), vehicle (v), and drug conditions. Intra-
tegmental rimonabant (200 ng i.c.; red bar) significantly decreased the
concentration of cue-evoked dopamine in comparison to vehicle.
(G) Representative dopamine concentration traces from individual trials after
vehicle (left; blue trace) and rimonabant (200 ng i.c.; right; red trace) treatment.
Traces represent individual data, bars represent mean values, and error
bars represent ± SEM. A significant difference versus vehicle is indicated by
either * (p < 0.01) or # (p < 0.05).
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sought to establish if disrupting the VTA endocannabinoid
system alone is sufficient to decrease dopamine neurotransmis-
sion by infusing rimonabant directly into the VTA during reward
seeking maintained in the ICSS task. As was found following
systemic treatment, intrategmental rimonabant (200 ng i.c.,
unilateral) significantly increased the latency to respond for brain
stimulation reward (Figure 2E; MWU test, U = 0, p < 0.01; n = 8;
mean values: b = 0.94, v = 1.10, rimo = 1.96 s) and decreased
cue-evoked dopamine concentrations (Figure 2F; F(2,14) = 7.01,
p < 0.01; 200 ng versus vehicle, p = 0.03; also see Figure S4A
for mean dopamine concentration traces). The representative
dopamine concentration traces (Figure 2G) show the effect of
intrategmental rimonabant on cue-evoked dopamine events in
individual trials. Rimonabant-induced decreases in cue-evoked
dopamine concentration during reward seeking maintained in
the ICSS task can also be observed in audio-visual format (Movie
S1). These data demonstrate that the VTA endocannabinoid
systemmodulates dopamine signaling during the pursuit of brain
stimulation reward.
Disrupting Endocannabinoid Signaling during Food
Self-Administration Decreases Cue-Evoked Dopamine
Concentrations and Appetitive Food Seeking
To assess whether disrupting endocannabinoid signaling also
decreases dopamine transmission during the pursuit of natural
reward, we treated animals with rimonabant while responding
was maintained in an appetitive food-seeking task (Supple-
mental Experimental Procedures). Similar to the ICSS task,
each lever response resulted in the delivery of food reinforce-
ment and retraction of the lever for 10 s. After each 10 s timeout,
a compound cue indicating reward availability was presented
simultaneously with lever extension. Rimonabant decreased
food seeking, as both a low (0.125 mg/kg i.v.; MWU test,
U = 4, p = 0.03; n = 6) and high (0.3 mg/kg i.v.; MWU test,
U = 0, p < 0.01; n = 8; mean values: b = 1.45, v = 1.82,
rimo = 17.7 s) dose increased response latency in comparison
to vehicle treatment (Figure 3A). Rimonabant was administered
prior to 60 responses, before animals reached satiety levels
(avg. of 200 reinforced responses). As in the ICSS task, an
increase in response latency was accompanied by a decrease
in the concentration of cue-evoked dopamine release (Figure 3C;
F(2,14) = 5.87, p < 0.01; 0.3 mg/kg versus vehicle, p = 0.04; also
see Figure S2A for mean dopamine concentration traces). Rimo-
nabant-induced decreases in cue-evoked dopamine concentra-
tion during individual (Figure 3D) and repeated (Figure 3E) trials
are illustrated in pseudocolor. Likewise, intrategmental rimona-
bant-induced increases in response latency (Figure 3F; MWU
test, u = 0, p < 0.01; n = 5; mean values: b = 1.18, v = 1.3,
rimo = 2.75 s) were accompanied by a decrease in cue-evoked
dopamine concentration (Figure 3G; F(2,14) = 9.86, p < 0.01;
200 ng versus vehicle, p = 0.014; also see Figure S4B for mean
dopamine concentration traces). Representative traces showing
the effects of vehicle and intrategmental rimonabant (200 ng
i.c., unilateral) on cue-evoked dopamine events are illustrated
in Figure 3H. Rimonabant-induced decreases in food seeking
can also be observed by viewing audio-visual material
(Movie S2). Together, these data demonstrate that disruptingthe VTA endocannabinoid system alone is sufficient to decrease
natural reward seeking.
Cannabinoid receptors are abundantly expressed throughout
the central and peripheral nervous system, however, and are
known to regulate consummatory behavior at a systems level
(Gomez et al., 2002; Berry and Mechoulam, 2002). We therefore
tested whether rimonabant-induced decreases in food seeking
can be explained by a decrease in consummatory behavior
rather than a decrease in appetitive food seeking by measuring
preferred meal size in an intraoral intake task (Supplemental
Experimental Procedures). Appetitive behavior involves a pursuit
of reward in the environment and is influenced by the motiva-
tional state of the animal (Bindra, 1968; Kelley, 1999), whereas
consummatory behavior involves the regulation of intake and is
reflected by an animal’s preferred meal size (Foltin and Haney,
2007). Intrategmental CB1 receptor antagonists did not produce
changes in cumulative intraoral intake (Figure 3B, right; t(6) =
0.3, n.s.) but significantly decreased intake when administered
systemically (Figure 3B, left; t(6) = 3.4, p < 0.01), suggesting
that the VTA endocannabinoid system exclusively regulates
appetitive aspects of feeding behavior.
Although the doses of rimonabant used in the present study
are comparable to those previously shown to reduce the
effects of environmental stimuli on motivated behavior without
producing nonspecific effects on locomotor activity (Le Foll
and Goldberg, 2004), we wanted to further assess whether our
reported decreases in reward seeking resulting from CB1
receptor antagonismmight be explained by a disruption in either
attentional processing or motor performance by assessing the
effects of rimonabant on behavior maintained in the five-choice
serial reaction time task. Rimonabant (0.3 mg/kg i.v.) failed to
disrupt visuospatial attention, as assessed by accurate choice
(Figure S2B) or motor performance, as measured by the latency
to respond to visual stimuli (Figure S2C). These data support that
the rimonabant-induced decreases presented herein are due to
a specific effect on reward seeking rather than nonspecific
behavioral effects on attention or operant performance.
Interval Timing, Dopamine Release,
and Endocannabinoids
In confirmation of our previous report (Cheer et al., 2007a), we
observed increases in dopamine concentration preceding cue
presentation (Figures 1B, 2C, 3D, and 3H). These data support
the theory that dopamine might function to encode information
related to interval timing, defined as the duration of time required
to organize a behavioral response, under conditions in which
reward availability is temporally predictable (Buhusi and Meck,
2005; Matell et al., 2003; Meck, 1996). To directly test this theory,
we compared changes in dopamine concentration during ICSS
conditions in which cue-presentation was predictable (fixed
time out = 10 s; FTO) versus conditions in which cue-presenta-
tion occurred variably (variable time out; = 30 s; VTO). As
occurred in the ICSS-FTO task, reward availability was signaled
to the animal by the presentation of a compound cue. This
signaled reward availability across multiple sensory modalities;
specifically, a house light turned off, an ongoing tone ceased
and a white stimulus light mounted above the lever was pre-
sented. All stimuli were presented simultaneously with leverNeuron 73, 360–373, January 26, 2012 ª2012 Elsevier Inc. 363
Figure 3. Disrupting Endocannabinoid Signaling Decreases Cue-
Evoked Dopamine Neurotransmission during Appetitive Food
Seeking
(A) Disrupting endocannabinoid signaling reduced reward seeking in a cued
food self-administration task. Rimonabant dose-dependently (0.125 mg/kg
i.v., orange bar; 0.3 mg/kg i.v., red bar) increased the latency to respond for
food reinforcement in comparison to vehicle (v, blue bar).
(B) Disrupting endocannabinoid transmission in the VTA specifically
decreased appetitive rather than consummatory feeding behavior. Systemi-
cally (left, red bar), but not intrategmentally (right, red bar) administered CB1
Neuron
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364 Neuron 73, 360–373, January 26, 2012 ª2012 Elsevier Inc.extension. As predicted, anticipatory dopamine (Figure 4A) was
only observed under FTO conditions. Importantly also, the
concentration of cue-evoked dopamine was significantly lower
under VTO conditions (Figure 4C; MWU test, U = 27.5, p =
0.032; n = 11), which likely reflects a decrease in value imposed
by the longer, unpredictable delays in reward availability occur-
ring in the ICSS-VTO task (Bromberg-Martin and Hikosaka,
2011; Day et al., 2010; Kobayashi and Schultz, 2008), while
response latencies were significantly increased (Figure 4B;
MWU test, U = 24, p < 0.01; n = 14) due to greater operandum
disengagement.
The data presented in Figure 2 demonstrate that rimonabant
decreased cue-evoked dopamine signaling and reward seeking
in the ICSS-FTO task. Under these conditions however, rather
than decreasing reward-directed behavior by interfering with
the neural representation of an environmental cue, disrupting
endocannabinoid neurotransmission might decrease reward-
directed behavior by interfering with an interoceptive timing
signal because pharmacological manipulation of either the
endocannabinoid or mesolimbic dopamine system can modu-
late neural representations of time during behavioral tasks
(Crystal et al., 2003; Meck, 1983, 1996; Taylor et al., 2007). To
address this, we tested the effects of rimonabant using the
ICSS-VTO procedure. Rimonabant significantly increased the
latency to respond in the ICSS-VTO task (Figure 4D; MWU
test, U = 0, p < 0.05; n = 4) as occurred in the ICSS-FTO task,
thereby supporting our hypothesis that endocannabinoids regu-
late reward directed behavior by modulating the encoding of
environmental cues predicting reward availability rather than
interfering with interval timing.
VDM11 Decreases Cue-Evoked Dopamine
Concentrations and Reward Seeking
We next sought to assess the effects of augmenting endocanna-
binoid levels on the neural mechanisms of reward seeking. Thereceptor antagonists decreased intraoral intake of a chocolate Ensure solution
in comparison to vehicle (v, blue bar), demonstrating that the VTA endo-
cannabinoid system does not affect an animal’s preferred meal size.
(C) Diminished appetitive food seeking is accompanied by a decrease in mean
dopamine concentration observed during the first second of cue-presentation
following rimonabant (0.3 mg/kg i.v., red bar) treatment.
(D) Representative color plots (top) and dopamine concentration traces
(bottom) show the effects of rimonabant (right, red trace) in comparison to
vehicle (left, blue trace) during individual trials.
(E) A representative surface plot illustrates changes in dopamine concentration
across trials (y axis) under baseline (black line), vehicle (blue line) and rimo-
nabant (red line) conditions.
(F) Disrupting endocannabinoid neurotransmission in the VTA is sufficient to
decrease appetitive food seeking. Intrategmental rimonabant (200 ng i.c.; red
bar) significantly increased response latency in comparison to vehicle (v, blue
bar).
(G) Rimonabant (200 ng i.c.; red bar) simultaneously decreased the mean cue-
evoked dopamine concentration in comparison to vehicle treatment.
(H) Representative traces illustrate that intrategmental rimonabant (200ng i.c.,
right, red trace) decreased the concentration of cue-evoked dopamine in
an individual trial in comparison to vehicle treatment (left, blue trace).
Traces represent individual data, bars represent mean values, and error
bars represent ± SEM. A significant difference versus vehicle is indicated by
either * (p < 0.01) or # (p < 0.05).
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Figure 4. Disrupting Endocannabinoid Signaling Decreases Reward
Seeking under Experimental Conditions that Do Not Recruit Neural
Mechanisms of Interval Timing
(A) Transient dopamine concentrations increase during the anticipation of
reward under conditions in which cue presentation is predictable (e.g., fixed
timeout [FTO] = 10 s) but not under conditions in which cue presentations
occur variably (variable timeouts [VTO] = 30 s). Representative mean (average
of 30 trials/condition) color plots (top) and corresponding dopamine concen-
tration traces (bottom) illustrate changes in dopamine concentration occurring
prior to cue presentation from the same animal responding for brain stimula-
tion reward under FTO (left) then VTO (right) conditions. Middle inset shows
a magnification of the color plots showing dopamine concentration increases
occurring prior to cue presentation.
(B) The mean latency to respond for brain stimulation reward was significantly
greater under VTO (light blue bar) in comparison to FTO (dark blue bar)
conditions.
(C) The mean dopamine concentration occurring during the first second of
cue-presentation was significantly decreased under VTO in comparison the
FTO conditions.
(D) Under VTO conditions, rimonabant (0.3 mg/kg i.v., red bar) significantly
increased the latency to respond for brain stimulation reward in comparison
to vehicle (v, blue bar). Traces and bars represent mean values while error
bars represent ± SEM. A significant difference versus vehicle is indicated by
either * (p < 0.01) or # (p < 0.05).
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involving response latency (as latencies to respond in the
ICSS-FTO task can be in the subsecond range for well-trained
animals). To increase endocannabinoid concentrations, animalswere treated with the putative endocannabinoid uptake inhibitor
VDM11 using a cumulative dosing approach. Contrary to our
hypotheses, VDM11 dose-dependently (300–560 mg/kg i.v.)
increased response latency (Figure 5A; F(2,23) = 5.69, p < 0.01;
560 mg/kg versus vehicle, p = 0.013; mean values: b = 1.25,
v = 1.26, 0.1 = 1.28, 0.3 = 4.47, 0.56 = 5.16 s) while decreasing
the concentration of cue-evoked dopamine release in a manner
similar to rimonabant (Figure 5B; F(4,29) = 3.66, p = 0.018;
560 mg/kg versus vehicle, p = 0.047; also see Figure S3A for
mean dopamine concentration traces). Figure 5C shows repre-
sentative color plots and dopamine concentration traces
illustrating the effects of vehicle (top) and VDM11 (bottom) in indi-
vidual trials. These findings suggest that, under these conditions,
VDM11 impairs the neural mechanisms of reward seeking by
functioning as an indirect CB1 receptor antagonist.
Repeated Vehicle Treatments Fail to Affect Cue-Evoked
Dopamine Concentrations and Reward Seeking
In addition to observing drug-induced decreases in cue-evoked
dopamine concentration however, we noted that the concentra-
tion of electrically-evoked dopamine also decreased across
trials (Figure S1A for Rimonabant; Figure S3A for VDM11). This
observation led us to test whether the decreases in cue- and
electrically evoked dopamine concentration were drug-induced,
or rather, the result of repeated vehicle injections occurring
in prolonged ICSS sessions. To address this, we measured
changes in NAc dopamine concentration and response latency
for brain stimulation reward in the ICSS-VTO task while adminis-
tering vehicle every 30 responses. Prior to ICSS-VTO session
onset, animals were first trained to criterion in the ICSS-FTO
task tomimic experimental conditions. Thus, rather than assess-
ing dopamine-release events during acquisition (Figure 1), this
experiment assessed dopamine concentrations over time as
would occur during pharmacological experiments. Best-fit
functions revealed that across trials cue-evoked dopamine
concentrations quickly increased to an unvarying maximal level
(Figure 6A; Exponential Rise to Maximum, Single, 2-Parameter;
R2 = 0.35; F(1,19) = 9.85, p < 0.01), while response latencies
quickly decreased to an unvarying minimal level (Figure 6B;
Polynomial, Inverse Second Order; R2 = 0.25; F(2,39) = 6.08,
p < 0.01). After the first 30 responses, both the concentration
of cue-evoked dopamine and response latency remained statis-
tically indistinguishable across binned responses. By contrast,
electrically evoked dopamine concentrations showed greater
variability and decreased linearly across trials (Figure 6A; Poly-
nomial, Linear; R2 = 0.31; F(1,19) = 7.90, p < 0.01). Representative
mean color plots and accompanying dopamine concentration
traces (Figure 6C) show dopamine concentrations changing
across binned-responses. Identical trends were observed in
untreated animals (data not shown). These observations are in
agreement with previous reports (Garris et al., 1999; Nicolaysen
et al., 1988; Owesson-White et al., 2008) that electrically evoked
dopamine concentrations, but not cue-evoked dopamine
concentrations or response strength, decrease during ICSS
sessions—an effect that has been attributed to the depletion of
a readily releasable pool of dopamine by electrical stimulation
(Nicolaysen et al., 1988; Owesson-White et al., 2008; Yavich
and Tiihonen, 2000). Moreover, these data demonstrate thatNeuron 73, 360–373, January 26, 2012 ª2012 Elsevier Inc. 365
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Figure 5. The Putative Endocannabinoid Uptake Inhibitor VDM11
Decreases Dopamine Mechanisms of Reward Seeking in a Manner
that Is Consistent with Indirect CB1 Receptor Antagonism
(A) VDM11 dose-dependently (300–560 mg/kg i.v., cumulative) increased the
latency to respond for brain stimulation reward in the ICSS-VTO task in
comparison to vehicle (v).
(B) Dopamine concentration observed during the first second of cue presen-
tation in the ICSS-VTO task under baseline (b), vehicle (v), or drug (VDM11
300–560 mg/kg i.v., cumulative) conditions. VDM11 dose-dependently
decreased the mean concentration of cue-evoked dopamine.
(C) Representative color plots (top) and dopamine concentration traces
(bottom) show the effects of VDM11 (560 mg/kg i.v., right, light blue line) and
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dopamine concentrations or response latency. These findings,
however, do not completely disprove that the endocannabinoid
system might modulate electrically evoked dopamine release.
The variables (e.g., route of administration, pharmacological
target) that might influence the actions of endocannabinoids
on electrically-evoked dopamine release should be further
addressed.
2AG but Not Anandamide Facilitates Reward Seeking
The VDM11 findings prompted us to investigate the specific
effects of the endocannabinoids 2AG and anandamide on
reward seeking. 2AG and anandamide levels are tightly regu-
lated through distinct enzymatic degradation systems. 2AG is
hydrolyzed by the enzyme monoacylglycerol lipase (MAGL),
whereas anandamide is hydrolyzed by the enzyme fatty acid
amide hydrolase (FAAH) (Cravatt et al., 1996; Long et al.,
2009). Recent advances in pharmacology have led to the devel-
opment of drugs that selectively inhibit either MAGL (JZL184;
Long et al., 2009) or FAAH (URB597; Cravatt et al., 1996; Fegley
et al., 2005; thereby producing specific increases in 2AG or
anandamide tissue levels, respectively. We began testing the
effects of these drugs in mice because JZL184 is known to
exhibit reduced potency against MAGL in rats (Long et al.,
2009). In mice, JZL184 (Figure 7A; F(2,14) = 6.61 p = 0.019;
40 mg/kg versus vehicle, p = 0.029), but not URB597 (data not
shown), increased break points (a metric of motivation) for
food reinforcement maintained under a progressive ratio
schedule (Supplemental Experimental Procedures). Importantly,
the JZL184-induced increase in break points was prevented
by pretreating mice with a subthreshold dose of AM251
(0.75 mg/kg i.p.), which demonstrates that the JZL184-induced
increase in motivation occurred in a CB1 receptor dependent
manner. In rats, we observed increased break points (Figure 7A
MWU test, U = 50.5, p = 0.026; n = 14) for food reinforcement
only after altering the route of administration and unit-injection
dose (10 mg/kg JZL184 i.v.). Using a cumulative dosing
approach, JZL184 (3–10 mg/kg i.v.) also facilitated reward
seeking as assessed by decreased response latency in the
ICSS-VTO task (Figure 7B; F(3,15) = 4.86 p < 0.01; 10 mg/kg
versus vehicle, p = 0.027; mean values: b = 4.02, v = 3.93,
3 = 3.83, 5.6 = 3.62, 10 = 4.32 s). By contrast, URB597 treatment
(10–56 mg/kg i.v.) was ineffective at altering response latency
(Figure 7C; mean values: b = 4.25, v = 4.19, 10 = 4.19, 31 =
6.15, 56 = 5.63 s) in the ICSS-VTO procedure, or break points
for food reinforcement maintained under a progressive ratio
schedule (Figure 7A). VDM11 (5.6 mg/kg i.v.) also failed to
affect break points for food reinforcement (data not shown). To
verify that JZL184 was indeed increasing activation of CB1
receptors, we treated rats with cumulative doses of JZL184
(5.6–10 mg/kg i.v.) while monitoring core body temperature as
cannabinoids produce hypothermia in rats (Garattini, 1965;vehicle (left, dark blue line) during individual trials of the ICSS-VTO task.
Dopamine traces represent individual data, bars represent mean values and
error bars represent ± SEM. A significant difference versus vehicle is indicated
by # (p < 0.05).
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Figure 6. Electrically Evoked, but Not Cue-
Evoked, Dopamine Concentrations Are
Partially Depleted during ICSS Sessions
(A) Electrically (light green) and cue (dark green)-
evoked dopamine concentrations across binned
responses. Animals are responding for brain
stimulation reward in the ICSS-VTO task during
repeated vehicle (1:1:18, v, blue arrow) treatments.
Under these conditions, cue-evoked dopamine
concentrations initially increased to maximum
and then remained stable throughout the duration
of the session. Conversely, electrically evoked
dopamine concentrations decreased linearly
across the duration of the session.
(B) Corresponding response latency values. The
latency to respond for brain stimulation reward
initially decreased to minimum and then remained
stable throughout the duration of the session.
(C) Representative mean color plots (top) and
corresponding dopamine concentration traces
(bottom) illustrate changes in dopamine concen-
tration occurring across binned responses.
Nonlinear regression functions show best-fit data
trends. Data points and dopamine traces repre-
sent mean data, and error bars represent ± SEM.
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core temperature across time (Figure 7D; F(3,34) = 2.63, p < 0.01).
To definitively test whether JZL184 increases 2AG levels
during reward seeking, we assessed lipid content in VTA tissue
from JZL184 and vehicle-treated rats upon completion of
the ICSS-VTO task and found that JZL184 significantly
increased 2AG VTA tissue content in comparison to vehicle (Fig-
ure 7E; t(27) = 2.07, p = 0.048), thereby confirming that JZL184
augments 2AG levels in the VTA during reward directed behavior
in the rat.
Increasing 2AG Levels Facilitates Cue-Evoked
Dopamine Release and Reward Seeking
To assess the effects of increasing 2AG levels on the neural
mechanisms of reward seeking we treated rats with JZL184
(10 mg/kg i.v.) while responding was maintained by brain stimu-
lation reward in the ICSS-VTO task. As observed using a cumula-
tive dosing approach, JZL184 (10mg/kg i.v.) decreased
response latency (Figure 8A; t(14) = 2.36, p = 0.033; mean values:
b = 3.55, v = 3.48, JZL = 2.89 s). Enhanced reward seeking
occurred in parallel with an increase in cue-evoked dopamine
concentration (Figure 8B; F(2,14) = 10.86 p < 0.01; 10 mg/kg
versus vehicle, p < 0.01; also see Figure S3B for mean dopamine
concentration traces). The effect of JZL184 on dopamineNeuron 73, 360–373signaling during individual trials is illus-
trated by the representative color plots
and accompanying dopamine concentra-
tion traces (Figure 8C), while the effect of
JZL184 on dopamine signaling across
trials is shown by the representative
surface plot (Figure 8D). To confirm that
2AG levels within the VTA are alone suffi-
cient to facilitate the neural mechanismsof reward seeking, we infused JZL184 into the VTA while
measuring dopamine concentrations and behavior maintained
in the ICSS-VTO task. Although the required vehicle to achieve
solubility (a 6 mg/0.5 ml solution required 100% dimethyl
sulfoxide [DMSO]) increased response latency; remarkably,
intrategmental JZL184 (6 mg, ipsilateral) reversed the DMSO-
induced deficits in reward seeking (Figure 8E; t(6) = 2.51, p =
0.046; mean values: b = 3.75, DMSO = 4.61, JZL = 3.47 s) while
increasing cue-evoked dopamine concentrations (Figure 8F;
F(2,18) = 10.84 p < 0.01; 6 mg versus vehicle, p = 0.023). To verify
that the effects of intrategmental JZL184 on reward seeking
were CB1 receptor dependent, we then treated rats with
a subthreshold dose of rimonabant (1.25 mg/kg i.v.), which
reverted response latencies to DMSO conditions. The effects
of intrategmental DMSO and JZL184 on cue evoked dopamine
events occurring in individual trials are illustrated by the
representative traces in Figure 8G, whereas the effects across
trials are depicted in a representative surface plot (Figure S4C).
JZL184-induced increases in cue-evoked dopamine concen-
tration and reward seeking can also be observed by viewing
audio-visual material (Movie S3). Taken together, these data
suggest that augmenting 2AG within the VTA is sufficient to
facilitate mesolimbic dopaminergic mechanisms of reward
seeking., January 26, 2012 ª2012 Elsevier Inc. 367
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Figure 7. The Endocannabinoid 2AG, but Not Anandamide, Facili-
tates Reward Seeking
(A) The effects of JZL184 (decreases degradation of 2AG) or URB597
(decreases degradation of anandamide) on break points for food reinforce-
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It is well documented that transient dopamine concentrations in
the NAc encode information regarding motivationally salient
stimuli that predict reward availability (Day et al., 2007; Flagel
et al., 2011; Phillips et al., 2003). Little is known however,
regarding how these transient increases are modulated at dopa-
mine cell bodies within the VTA. In the present study, we used
a cutting-edge electrochemical monitoring technique to investi-
gate how endocannabinoids in the VTA modulate transient
dopamine release into the NAc shell during reward seeking.
We found that disrupting endocannabinoid modulation of dopa-
mine neurons reduced cue-evoked dopamine concentrations
and reward seeking. Moreover, we identified that 2AG, rather
than anandamide, is the primary endocannabinoid responsible
for facilitating the neural mechanisms of reward seeking. Thus,
our findings reveal that the VTA endocannabinoid system is crit-
ical for the fine-tuned regulation of dopamine signaling that
mediates reward-directed behavior.
Our data demonstrate the existence of a single neural
signaling mechanism through which CB1 antagonists can effec-
tively diminish the influence that environmental cues exert over
motivated behavior. A number of studies have shown that the
endocannabinoid system is involved in the appetitive-motiva-
tional aspects of reward-directed behavior. For example, moti-
vation for both palatable foods (Ward and Dykstra, 2005) and
drugs of abuse (Solinas et al., 2003; Xi et al., 2008) is decreased
by pharmacological disruption of endocannabinoid signaling as
assessed by break points under a progressive ratio schedule.
A current theory holds that endocannabinoids are specifically
involved in modulating the secondary/environmental influences
on motivated behavior (Le Foll and Goldberg, 2004; De Vries
and Schoffelmeer, 2005). In support of this view, when operant
behavior is maintained by conditioned cues (i.e., under a second
order schedule), pharmacological disruption of endocannabi-
noid signaling decreases responding (Justinova et al., 2008).
Moreover, endocannabinoid disruption is particularly effective
at reducing cue-induced reinstatement, a model of relapse in
humans that incorporates the influence of conditioned environ-
mental stimuli on reward seeking (Epstein et al., 2006). In thisment maintained under a progressive ratio schedule. Left: In mice, JZL184
(40 mg/kg i.p., purple bar) increased break points for food reinforcement in
comparison to vehicle (v, green bar). Pretreatment with a subthreshold dose of
AM251 (0.75 mg/kg i.p.) prevented the JZL184-induced increase in break
point. Middle: In rats, JZL184 (10 mg/kg i.v.) produced a significant increase in
mean final ratio when compared to vehicle. Right: In rats, URB597 (56 mg/kg
i.v., yellow bar) failed to increase the break points for food.
(B and C) JZL184 (3–10 mg/kg i.v. cumulative) but not URB597 (10–56 mg/kg
i.v., cumulative) decreased response latency for brain stimulation reward in the
ICSS-VTO task in rats.
(D) Topographic plot showing core temperature of rats (z axis) over time (y axis)
under baseline (b), vehicle (v), and JZL184 (5.6 then 10 mg/kg i.v. cumulative)
conditions.
(E) JZL184 (10mg/kg i.v., purple bar) treated rats showed a significant increase
in 2AG VTA tissue content in comparison to vehicle treated rats. Tissue
samples were collected immediately after ICSS-VTO sessions. Bars represent
mean ± SEM values. A significant difference versus vehicle is indicated by
either * (p < 0.01) or # (p < 0.05).
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Figure 8. The Endocannabinoid 2AG Facilitates Dopaminergic
Mechanisms of Reward Seeking
(A) Augmenting 2AG levels facilitated reward seeking in the ICSS-VTO task.
JZL184 (10 mg/kg i.v., purple bar) decreased response latency in comparison
to vehicle (v, blue bar).
(B) Facilitated reward seeking was accompanied by an increase in cue-evoked
dopamine concentration.
(C) Representative color plots (top) and dopamine concentration traces
(bottom) show the effects of JZL184 (right, purple trace) in comparison to
vehicle (left, green trace) during individual trials.
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Endocannabinoids Regulate Dopamine and Motivationmodel, CB1 receptor antagonists decrease the propensity for
conditioned cues to reinstate responding for appetitive food
(Ward et al., 2007) and various drugs of abuse (Justinova et al.,
2008; De Vries and Schoffelmeer, 2005). Importantly, the finding
that disrupting endocannabinoid signaling decreases reward
seeking regardless of the reinforcer paired with the cue (De Vries
and Schoffelmeer, 2005) implies that a common neural mecha-
nism is involved through which endocannabinoids regulate
cue-motivated behavior. Our data suggest that this common
neural mechanism involves endocannabinoid disinhibition of
cue-evoked dopamine cell firing in the VTA, as pharmacological
disruption of endocannabinoid signaling within this brain region
was sufficient to decrease cue-evoked dopamine concentra-
tions and reward seeking behavior in unison. It is likely that
following systemic administration of CB1 receptor antagonists;
however, diminished surges in dopamine concentration interact
with altered accumbal glutamate concentrations (Xi et al., 2008),
possibly arising from the prefrontal cortex (Alvarez-Jaimes
et al., 2008), to decrease reward seeking. Such an interaction
would be consistent with the theory that accumbal dopamine
affects reward seeking by modulating convergent cortical,
hippocampal, and amygdalar input (Brady and O’Donnell,
2004; Floresco et al., 2001). Furthermore, CB1 receptors within
the NAc likely contribute to decreased reward seeking following
systemic administration of CB1 receptor antagonists (Alvarez-
Jaimes et al., 2008). Nevertheless, our findings that intrategmen-
tal disruption of endocannabinoid signaling alone simultaneously
decreased cue-evoked dopamine concentrations and reward
seeking suggests that the VTA endocannabinoid system is criti-
cally involved in mediating cue-motivated reward-directed
behavior.
We therefore predicted that increasing endocannabinoid
levels would facilitate the neural mechanisms of reward seeking.
VDM11 however, dose-dependently decreased cue-evoked
dopamine signaling and reward seeking in a manner that is
more consistent with VDM11 reducing presynaptic CB1 receptor
activation. These findings are in agreement with recent reports
demonstrating that endocannabinoid uptake inhibitors can
decrease cue-induced reinstatement of drug-seeking behavior
in a manner similar to rimonabant when assessed using self-
administration (Gamaleddin et al., 2011) or conditioned place
preference paradigms (Scherma et al., 2012). One possible
mechanism explaining these findings is that VDM11 decreases(D) A representative surface plot illustrates changes in dopamine concentra-
tion across trials (y axis) under baseline (black line), vehicle (green line), and
rimonabant (purple line) conditions.
(E) Augmenting 2AG in the VTA is sufficient to facilitate reward seeking.
JZL184 (6 mg, ipsilateral, purple bar) decreased response latency in compar-
ison to DMSO (green bar). Posttreatment with a subthreshold dose of rimo-
nabant (1.25 mg/kg i.v.) reversed the JZL84-induced decrease in reward
latency.
(F) Facilitated reward seeking occurred simultaneously with an increase in cue-
evoked dopamine concentration in comparison to vehicle.
(G) Representative traces show the effects of intrategmental vehicle (left, green
trace) and JZL184 (right, purple trace) on cue-evoked dopamine concentration
in individual trials. Traces represent individual data, bars represent mean
values, and error bars represent ± SEM. A significant difference versus vehicle
is indicated by either * (p < 0.01) or # (p < 0.05).
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release of endocannabinoids through a putative transport
mechanism (Hillard et al., 1997; Melis et al., 2004; Ronesi
et al., 2004). Another mechanistic explanation is that VDM11
might selectively increase anandamide (van der Stelt et al.,
2006), which could function as a competitive antagonist at
CB1 receptors in the presence of 2AG because, in contrast to
2AG, anandamide is a partial agonist at CB1 receptors (Howlett
and Mukhopadhyay, 2000). These findings led us to investigate
the respective contributions of 2AG and anandamide. 2AG,
but not anandamide, increased motivation, reward seeking,
and cue-evoked dopamine concentrations. These data demon-
strate that 2AG is the primary endocannabinoid that enhances
the neural mechanisms of cue-motivated reward seeking and
agree with reports demonstrating that 2AG is the principal
endocannabinoid for multiple forms of synaptic plasticity across
several brain regions (Melis et al., 2004; Tanimura et al., 2010).
Based on our data, we speculate that 2AG might modulate
cue-evoked dopamine release through disinhibition of dopamine
neurons in the VTA. When dopamine neurons fire at high
frequencies they release 2AG (Melis et al., 2004), which then
retrogradely binds to CB1 receptors on presynaptic terminals
within the VTA (Lupica and Riegel, 2005). Although 2AG would
affect both GABAergic and glutamatergic synaptic input through
CB1 receptor activation (Ma´tya´s et al., 2008)—cue-encoding
VTA dopamine neurons are theorized to form discrete neural
assemblies with GABAergic synapses, thereby allowing for
the fine-tuned regulation of dopamine neural activity during
reward seeking (Lupica and Riegel, 2005; Ma´tya´s et al., 2008).
According to this conceptualization, 2AG activation of CB1
receptors located on GABAergic terminals might decrease
GABA release onto VTA dopamine neurons. The reduced
GABA tone theoretically would decrease activation of GABA
receptors on VTAdopamine neurons, thus resulting in a disinhibi-
tion of dopamine neural activity (Lupica and Riegel, 2005). The
resulting disinhibition of dopamine neural activity is theorized
to facilitate the neural mechanisms of reward seeking. It is impor-
tant to clarify that using this freely moving recording approach,
other mechanisms within the VTA may account for the observed
findings.
We further speculate that endocannabinoid modulation of
dopamine release from the VTA might affect NAc neural activity
through a D1 receptor dependent mechanism. While recent
evidence indicates that dopamine does not directly change
postsynaptic excitability in the NAc (Stuber et al., 2010; Tecua-
petla et al., 2010), it remains well accepted that dopamine can
modulate input into the striatum, as occurs during reward
seeking, to affect neural responses in a D1 receptor dependent
manner (Cheer et al., 2007a; Goto and Grace, 2005; Reynolds
et al., 2001). It is possible therefore, that the VTA endocannabi-
noid system might affect NAc neural activity by increasing D1
receptor occupancy. Recently developed computational models
of dopamine signaling offer insight into how dopamine transients
might influence NAc neural activity specifically through a D1
receptor-mediatedmechanism (Dreyer et al., 2010).When dopa-
mine neurons exhibit regular pacemaker firing, low concentra-
tions (i.e., tonic) of dopamine are released throughout the
NAc (Floresco et al., 2003). The computational model predicts370 Neuron 73, 360–373, January 26, 2012 ª2012 Elsevier Inc.that during tonic dopamine signaling, D2 receptors approach
maximal occupancy whereas D1 receptors remain relatively
unaffected (Dreyer et al., 2010). By contrast, when dopamine
neurons fire at high frequency, transient bursts of dopamine
are heterogeneously released into discrete microcircuits of
the NAc (Dreyer et al., 2010; Wightman et al., 2007). When
these higher concentration transients occur—D1 receptor
occupancy theoretically increases precipitously whereas D2
receptors, which are already approaching maximal occupancy,
remain relatively unaffected (Dreyer et al., 2010). Thus, we
hypothesize that endocannabinoid disruption in the VTA might
decrease NAc neural activity by preventing sufficient D1
receptor occupancy.
The present study offers previously unseen insights regarding
the neural mechanisms underlying reward seeking motivated by
conditioned cues. Our data demonstrate for the first time that
2AG within the VTA can modulate cue-evoked dopamine tran-
sients, which are theorized to promote reward seeking (Nicola,
2010; Phillips et al., 2003). While we (Cheer et al., 2007b) and
others (Perra et al., 2005) have demonstrated that disrupting
the VTA endocannabinoid system decreases drug-induced
dopamine release, this is the first demonstration that the endo-
cannabinoid system modulates cue-evoked dopamine tran-
sients during the pursuit of reward. Furthermore, our data
suggest that drugs designed to specifically manipulate 2AG
levels may prove to be effective pharmacotherapies for the treat-
ment of neuropsychiatric disorders involving amaladaptivemoti-
vational state.
EXPERIMENTAL PROCEDURES
Subjects
Male Sprague-Dawley rats, 90–120 days old (300–350 g), fitted with back
mounted jugular vein catheters at vendor (Charles River) were used as
subjects. Subjects were anesthetized with isoflurane (5% isoflurane induction,
2% maintenance) in a Kopf stereotaxic apparatus and implanted with a
microdialysis guide cannula (BAS) aimed at the NAc shell (+1.7 AP, +0.8 ML),
an ipsilateral bipolar stimulating electrode (Plastics One) in the VTA
(5.4 AP, +0.5 ML,8.7 DV), and a contralateral Ag/AgCl reference electrode.
All procedures were performed in accordance to the University of Maryland,
Baltimore’s Institutional Animal Care and Use Committee protocols.
Fast-Scan Cyclic Voltammetry
Dopamine was detected from fast-scan cyclic voltammograms collected at
the carbon fiber electrode every 100 ms (initial waveform: 0.4V to 1.3V,
400V/s [Heien et al., 2003]). Principal component regression (PCR) was used
as previously described to extract the dopamine component from the raw
voltammetric data (Heien et al., 2005).
Dopamine Signal Calibration
Principal component regression (PCR) was used as previously described to
extract the dopamine component from the raw voltammetric data (Heien
et al., 2005). A calibration set of stimulations was obtained for each experiment
varying number of stimulation pulses (6, 12, or 24) and frequency (30 or 60 Hz).
Scaling factors for both DA and pH were obtained post experiment by placing
the electrode into a flow injection system and injecting known concentrations
of DA and pH into artificial cerebrospinal fluid. These scaling factors related
current values to concentration values.
Microinfusions
For experiments involving intrategmental infusions, rats were unilaterally
treated with vehicle (DMSO; 0.5 ml), rimonabant 200 ng/0.5 ml or JZL184
Neuron
Endocannabinoids Regulate Dopamine and Motivation6 mg/0.5 ml. Infusions occurred in the experimental chamber using a micropro-
cessor-controlled infusion pump (Harvard Apparatus). An infusion needle was
inserted through a guide cannula ending 1mm above the tip of a bilateral stim-
ulating electrode (Plastics One); the needle was cut to extend 1mmbeyond the
cannula tip.
Histology
Rats were placed under deep anesthesia (2 mg/kg urethane). A high amplitude
current (500 mA) was applied through a stainless steel electrode to verify
working electrode placement. Rats were then intracardially perfused with
saline, potassium ferrocyanide stain, and 10% formalin. Brains were removed,
cryoprotected, and coronally sectioned using a cryostat. See Figure S5 for
representative illustrations confirming electrode placement.
Statistics
Behavioral analyses were statistically evaluated using the Shapiro-Wilk test for
normality. If not normally distributed, data were analyzed with either theMann-
Whitney U (MWU) test or Kruskal-Wallis ANOVA on ranks. If normally distrib-
uted, data were analyzed with either the Student’s t test or ANOVA. Dopamine
concentrations occurring during the first second of cue presentation were
analyzed with ANOVA and Bonferroni post-hoc tests. All statistical analyses
were performed with SigmaPlot (version 11).
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, three movies, and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.neuron.2011.11.018.
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